Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.

Abstract: The present invention provides a novel human protein, SATB1, that binds matrix/scaffold-associating DNA regions (MARs). The novel human protein, predominantly expressed in the thymus, has an approximate molecular weight of about 85.9 kD. The SATB1 cDNA encodes a 763 amino acid sequence protein that is capable of binding to special AT rich sequences (ATC sequences). The invention further provides antibodies specifically reactive with such protein. Isolated nucleic acids encoding the novel MAR-binding protein are also provided, as well as vectors containing the nucleic acids and recombinant host cells transformed with such vectors. The invention further provides methods of detecting such nucleic acids by contacting a sample with a nucleic acid probe having a nucleotide sequence capable of hybridizing with the isolated nucleic acids of the present invention. Such probes can correspond to the ATC sequences.

Abstract: Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an IgG and thereby have increased circulatory half-life.

Abstract: The present invention relates to cDNAs encoding murine antibodies against apolipoprotein B-100. In addition, the present invention relates to methods of preparation of recombinant antibodies specific for human plasma apolipoprotein B-100 of LDL, and use thereof, for diagnosis and treatment of cardiovascular diseases.

Abstract: The present invention provides a method for treating the inflammatory response of an established colitis in a subject with inflammatory bowel disease (IBD), comprising administering to a subject diagnosed with an established colitis from an IBD an amount of an antibody to interleukin-12 effective in reducing the colitis-inducing effect of interleukin-12. Also provided is a method for screening a substance for its effectiveness in reducing the inflammatory response of an established colitis comprising obtaining an animal having an established colitis; administering the substance to an animal; and assaying the animal for an effect on interleukin-12 which results in the reduction of the inflammatory response of the colitis, an amount of reduction of the inflammatory response greater than the amount of reduction produced by the administration of antibodies against interferon-gamma or tumor necrosis factor-alpha indicating an effective substance.

Abstract: The present invention presents an antigenic peptide whose amino acid sequence comprises a fragment of the caseinomacropeptide (CMP) sequence, which peptide is characterized in that it carries at least one epitope of CMP. These peptides exhibit no or little cross-reactivity with K-casein. When these peptides are used as immunogens, they make it possible to obtain specific anti-CMP antibodies. Also disclosed is a process for detecting the presence of cow's milk CMP in milk and milk products, using the above antibodies. Further presented are diagnostic reagents for the assay of CMP, which reagents are characterized in that they comprise at least one peptide, antigenic composition, or anti-CMP antibody of the present invention.

Abstract: An hematopoietic progenitor cell antigen, and antibodies that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34.sup.bright, and contains substantially all of the CFU-GM activity present in the CD34.sup.+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen may be further purified by selection for other hematopoietic stem cell and progenitor cell markers.

Abstract: The present invention provides a human proline-rich membrane protein (PRMP) and polynucleotides which identify and encode PRMP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PRMP and a method for producing PRMP. The invention also provides for agonists, antibodies, or antagonists specifically binding PRMP, and their use, in the prevention and treatment of diseases associated with expression of PRMP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding PRMP for the treatment of diseases associated with the expression of PRMP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding PRMP.

Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.

Abstract: A method for identifying non-sex specific and sex specific molecules associated with animal cell membranes is described. The method involves preparing a cell membrane fraction from adult, fetal, or embryonic animal cells; treating the cell membrane fraction with one or more substances which bind to non-sex specific molecules in the cell membrane fraction to form conjugates between the non-sex specific molecules and the substances; separating the material in the cell membrane fraction which does not bind to the substances to obtain a subfraction containing sex specific molecules; optionally, removing the substances in the conjugates to obtain a subfraction containing non-sex specific molecules; and, isolating the sex specific molecules and optionally non-sex specific molecules in the subfractions. Sex specific and non-sex specific molecules and methods of using the sex specific and non-sex specific molecules for sexing are also described.

Abstract: Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

Abstract: DNA encoding a novel human .beta..sub.2 integrin .alpha. subunit polypeptide, designated .alpha..sub.d, is disclosed along with methods and materials for production of the same by recombinant procedures. Fusion proteins are also disclosed which include extracellular .alpha..sub.d protein fragments, .alpha..sub.d I domain fragments or full length .alpha..sub.d polypeptides and human immunoglobulin constant regions. Binding molecules specific for .alpha..sub.d are also disclosed as useful for modulating the biological activities of .alpha..sub.d. DNA from other species which show homology to human .alpha..sub.d encoding sequences are also disclosed.

Abstract: The present invention provides novel megakaryocyte differentiation factors, which are useful as therapeutic agents due to their accelerating effects on the differentiation of megakaryocytes and their thrombopoietic effects. The megakaryocyte differentiation factors of the present invention include the megakaryocyte differentiation factor having the amino acid sequence shown in SEQ ID NO: 34. The present invention also provides DNA coding for the megakaryocyte differentiation factors of the present invention, expression vectors containing the DNA, hosts transformed with the expression vectors, and processes for production of the megakaryocyte differentiation factors using transformed hosts. The present invention further provides specific antibodies to the megakaryocyte differentiation factors of the present invention.

Abstract: A chimeric compound that contains a cell-specific ligand linked to a pore-forming agent capable of lysing a cell.

Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.

Abstract: Proteins produced by human lymphocytes are described, particularly a protein which is expressed on their surface. DNA sequences coding these proteins and their pharmaceutical and biological uses are also described.

Abstract: Disclosed is a method of inhibiting a rejection response by a primate to a transplanted organ. One exposes the primate to a mutant diphtheria toxin linked to anti-CD3 antibody so as to largely eliminate the host's peripheral blood T cell lymphocyte population. At the same time as, or after, the exposure step one administers to the primate's thymus gland donor lymphocytes. Transplantation of the organ follows. The primate is tolerized to the transplanted organ.

Abstract: There is provided an isolated immunoglobulin comprising two heavy polypeptide chains sufficient for the formation of a complete antigen binding site or several antigen binding sites, wherein the immunoglobulin is further devoid of light polypeptide chains.

Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1a (murine flk-2), FIG. 1b (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1a, FIG. 1b and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.

Abstract: A method for increasing feed conversion efficiency in mammals, such as swine, wherein the mammal is fed a diet containing an antibody produced using the enzyme urease as the antigen.